Stratpharma’s wound care and scar management portfolio is now available in the US, according to Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company.

The portfolio includes:

Stratacel, a film-forming wound dressing developed specifically for sensitive skin areas including the periorbital region, lips, and nostrils. Stratacel is especially effective for laser resurfacing procedures.

Stratamed, the first film-forming gel based wound dressing approved for the immediate use on open wounds and compromised skin. This can be applied immediately after all dermatological interventions including burns (1st and 2nd degree burns; 3rd degree burns after the presence of granulating tissue) for rapid re-epithelialization and abnormal scar management.

Strataderm, the only once-per-day topical application for scar management. Strataderm is a rapidly drying, non-sticky, transparent, silicone gel formulation for the treatment of both old and new scars, as well as abnormal scar management, in the form of hypertrophic scars and keloids. 

Stratpharma also plans to introduce Stratamark, a new product for the treatment and prevention of stretch marks, in the near future, with U.S. clinical trials currently underway.

Stratpharma Inc. USA will focus on informing and educating the U.S. medical community, including dermatologists, plastic surgeons, radiation oncologists, and OBGyns, as to how these topical medical devices.